{"ticker": {"uuid": "61cdb5df-b2b3-498c-99fe-f44983250901", "symbol": "XOMA", "name": "XOMA Royalty Corporation", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Form 13D/A XOMA Royalty Corp For: 16 July By Investing.com", "summary": "This article reports on a Form 13D/A filing by XOMA Royalty Corp for July 16, 2026. The filing is a standard disclosure document related to equity ownership. The content primarily consists of navigational elements and market data, with the filing announcement being the central pi", "url": "https://ng.investing.com/news/stock-market-news/form-13da-xoma-royalty-corp-for-16-july-93CH-2604017", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T02:39:10", "published_display": "17 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) holders tender shares in Ligand merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPaXNxb3V4MDZMY21VWUN2VGRrZFo2eGJLOURfVmJCMGdaZ2x6UGtZWXRRZ0czOW1hUEltaDU4NFBPaUlRUTNMSWRXVUhsa0RWTlZTQWpkTDBONXRLTjNpX3RFa0FYTElkZFhQTk5qRUxFYTZ4TldZZ2RlcnZONTc3UUR2X0hfMHJvd0licDBTRkhSQUo0ckppaVNLdFBGRllRU01pcGQ3WW9ZWDVBMnRHcQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T21:03:19+00:00", "published_display": "16 Jul 2026 21:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) investors cashed out at $39 per share in Ligand merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPQ1diQmdFalRMN1JqVlo4NDlldl9PbjdBbS1iVF9oQ0NVaDh5QWU5U1IyaHkyWndmclR3b25Wb2JYTzVTTHdpaFl3T2JYWU1LNVVvRGdWeDY4SEpzb0p5WWVXMmFWSnNiNmRhUGF0SU0zZ0Joel84T2hKLXF4ZEZqUmZGNl9SWTBiS1BTcmhBWm5GYmtHX09NRHlfbW1DdFNzVDhFcXBoaHVBekF3cnlBelMyUmhOcHdaSTBqdUJrb3h6NVFjeVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T21:01:11+00:00", "published_display": "16 Jul 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "XOMA Royalty Corp (NASDAQ: XOMA) files Form 25 to delist preferred shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPb2lvZlVrZHlGRWVBelFiWEJHdzlPakg5cGhKRWZrTGwxWkQ0SzlDSVU2NVBZZl9mdzhGY2FfYlZSYjdTRkxJTjBRU3puMG9pVnUtWVFzSk5SOU5zREdzcFRVXzBDM2xlbkZqMDI1N0trd3o1eXR1N3k0aTBsS2xrV3lMVEwtTHFHdGZXaHFGTURHN3Y0SU8zSVFUc3Nfdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:31:41+00:00", "published_display": "16 Jul 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (Nasdaq: XOMA) common stock removed from Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcDdKSElNSGpjbzdxWWE2Y1FGY29obXprM2FOSDJwQTQxamhTdUxLUW95T1Vja2V1SlBJMGhCRG8tZXR6bVhZLS1NM2l6MnZNSEdaWGhZRXJEY0tTN0xGNUx0X1dqNFdvVFY3SlNrX05Oc014TExQLXVlRjFFQlVRUExHRWRuWE9lS0hKU1V6Sk84UkVJS0JnRzc2M1d6UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T14:39:49+00:00", "published_display": "15 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (NASDAQ: XOMA) director\u2019s stock canceled in $39 cash-and-CVR deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNZUN5T3BaNDJNQXpQdVdsNVlwZ3BtWEFNLU9YTmNIcGl0RS1VOUg4am8zSjBwQzlBZFBIYlVjaTN5dE5TRk1LZVVkdmszeUsySTdINWVnN2JocDktYW1vUFlNTXFDNUgtak1Yd290N2thc0p6MHhIQjRWTTRoRm9iU2JadlJIeUg4X0VXMHVxeVdYQ1RSWHRxaWx5NklKSUc1aHNwU1lpcmVlM1JFdmVscw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T02:15:09+00:00", "published_display": "15 Jul 2026 02:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) legal chief\u2019s stock and PSUs converted in Ligand merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOWFE0YnZROHY5by1oS2U3UkUzaHZmZ19hSFRnUGpPSGwzeXdjWW9Fc2p2eW5fUzFjdVVSbVR3NkN3WDNmOVFSTS1maXllTTduNGZYMjBHZTJ2eTl4MWI1NjlBSWRfUzFXci01WFNJVGhXN29jbEV4Z1B2c2NEcV9aWjlObkxfTXBzM3piZVVxTGstUVFsLXdWTWFHOFltY2JxeVZBQWtIay13djE0NDE2SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T02:15:09+00:00", "published_display": "15 Jul 2026 02:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) CEO cashes out at $39 per share in Ligand merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQVGtFSmY2Nm14Wld5MVdlMnJnZEdHWENfaE44TmlrM19kWnlJSzZkQm9rNDhlbjlTeHd6andGWEFWX2RZNzVSaGo0SkJCRXg4X25KODZHOVFpTHluQjJUbEdPdzFnX2V5LXlTUUtCWEZvdVpUZUpIaGV5QkpQb25BSlJyQTZDWG9QMGVCaTlmcnRsOEtWbnRHSUx3M3pDMDhSamx2UzY5RWlfMDF1dFRsMw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T02:15:09+00:00", "published_display": "15 Jul 2026 02:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) director exits stake as shares convert to $39 cash and CVRs", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNcDY5VC1uZHhWY3BuZDJNbVRuMnRTZkdRZDFEcEVGZW53dk9yOWdPUUpWRklqWG5mbV9KVnFteWxyNmVBVU5wT1NQX0pvc21qTS00aUxYckZ4SzNaTHlCc1ZtdXlNVnVTR241ZERXaWFaZGxYWENKaG5hbVZmcm94UENCblhqZV9LRWZfY3Zmc1NsWXpLcjgyQ1RKX3J0c2FyaGJmNGo3QUNEUDRYOF9MNg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T02:15:09+00:00", "published_display": "15 Jul 2026 02:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand merger cashes out XOMA Royalty Corp (XOMA) director\u2019s shares and options", "summary": "XOMA Royalty Corp director Jack L. Wyszomierski reported the disposition of 21,828 common shares and the cancellation of all stock options due to XOMA's merger with Ligand Pharmaceuticals. Each share was converted into the right to receive $39.00 in cash plus contingent value rig", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-6f67b0ba9a58.html", "source_name": "Stock Titan", "published_at": "2026-07-15T02:44:20", "published_display": "15 Jul 2026 02:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ligand-pharmaceuticals-closes-739-million-140015736.html", "source_name": "MT Newswires", "published_at": "2026-07-14T14:00:15+00:00", "published_display": "14 Jul 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Announces Closing of Its Acquisition by Ligand", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxORE84QkVUVG5LRnpVOGZxdkNhMnpIb0JJc1hwRkpNLXQ0SnlzbWFnUUhVWjV1Vlk2c3U1VTJ3T3Q3UTRPbW1iZU1rZ1g2WllVLW9kOV9uSjN3VmdhN196R2JwZFphRGsybFR2S2RGTGFaWDlhWEhpU0E1aEpCSnhUaWlSTDEtaFNNdkp5ZzdmcTNacG9WRlVvd2tnYXJORjdCcjM4dVd3?oc=5", "source_name": "Market source", "published_at": "2026-07-14T13:00:00+00:00", "published_display": "14 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ligand-completes-acquisition-xoma-royalty-130000838.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T13:00:00+00:00", "published_display": "14 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand\u2019s Portfolio Now Tops 200 Biopharmaceutical Royalty Assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcTBHWFJ3d25VTVZ3M2JScUhyTkIxZnZvTE02eDFOcXV3MTh2VS1DaVdRT1oyUlRpMnZCdFVhWm9TYm1yV1p5TXBMMHVoZ1pmUFoyYmhLbDB3SUJYYXVJeng2dE5zRlVWYmYydTRFSmFsVUNYZ2Rsbzd5eDJRSXFBdVNKTWdCQ1VQbS1TODA3UXJVcklXd0ppTFZKTThZQzRGcDNuQjhxWml4MUE1MEhRMFhTUnNiR19WbkxyVHM4V0c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Leaves Nasdaq as Ligand Acquisition Closes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMFhRT3FvZEdkbFRlYXB0SWhKczR4eVBUdmxqZEJHN0tmWWl6OVp2RENXNEo2WGN4LXg0dzhSNzNGRTE0c0FNWDgwellaTnVXZnU1eEF6anQ3RHhVcFpMWXdhRGh6bk55QjlRZDhPWDdmNnFKNmtMeUNiOHZrYXNydUw5Q0ZrSG5qcDAyVlRpd3Q1TWZGZFpjZGljYkhIbC1yS0ptZ2sxT3J0cWs?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNYUtTTU51VF92YnF6MUVla010MzV4OGJfLWJWUXZoUURHOE5HOW9aWWNaVy1KWUVId1JyMElrTXBUTEl1LTdRel9jYkhsZlFsTGZYNDRSTDJxYktFVnRqTll0MGpDWVVuLXRGTnh3Zjk2eE5yWGJHTUlJQi1walNSYW9ia0hBdGJFamNLaThFXzFXa2FqaUJKYw?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) to redeem all preferred shares and issue CVRs ahead of Ligand deal", "summary": "XOMA Royalty Corporation announced plans to redeem all outstanding Series A and Series B preferred shares on July 14, 2026, at $25.00 per share plus accrued dividends, ahead of its acquisition by Ligand Pharmaceuticals. The company also declared quarterly dividends for these pref", "url": "https://www.stocktitan.net/sec-filings/XOMAP/8-k-xoma-royalty-corp-reports-material-event-91a4127e2a53.html", "source_name": "Stock Titan", "published_at": "2026-06-13T00:40:31", "published_display": "13 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corporation Declares Quarterly Preferred Stock", "summary": "XOMA Royalty Corporation announced cash dividends for its Series A and Series B Preferred Stockholders, with dividend payments scheduled for July 15, 2026. The company also declared its intention to redeem all outstanding shares of Preferred Stock on July 14, 2026, coinciding wit", "url": "https://www.globenewswire.com/news-release/2026/06/12/3311310/0/en/XOMA-Royalty-Corporation-Declares-Quarterly-Preferred-Stock-Dividend-and-Announces-Redemption-of-Its-Perpetual-Preferred-Stock-and-CVR-Dividend-Record-Date.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T20:10:05", "published_display": "12 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNU2JjaC0tQUh0d2M5dFI3NExCTW9YMW41OTFYMzFXdndiUEQ1aFpDVGhJUGRwdzJjajhISks4VEVETnBFLXdrcG90ck1PYzMxSDhlc0gzZDhWUkhJekVaLS03VldYUUpaZHA3WVBuZ3dJYVh4RFcxZGpiS0t4SlU3alNKSVZjWTN1ZFZpUTdHQUF6VXFPZXhMOFFtME1xQXdRM0QySzRHTGl3bXNh?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Saying Goodbye To The XOMA Royalty PFDs (NASDAQ:XOMAO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNZTlxak5hLWtjRXZXS3h6NG5yMkJmS0xNa0pEdXZRWTZfTUxWbVR1Q002dFphSnMxdk9aWG1GNVB2b2ZDSU1NY2x3TTBqampMZUdyT0R2UFJpVFNXcW5NZDh5SElqSHBaZ2xKN2x2WDVZV2VPTGpCTVZVLWlCOWp0N0h5ZTZzb1U?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (XOMA) adds new holding company to structure of Ligand acquisition", "summary": "XOMA Royalty Corporation has updated the structure of its acquisition by Ligand Pharmaceuticals by adding a new wholly-owned subsidiary, XOMA Royalty Holdings Corporation (HoldCo), to facilitate a holding company reorganization under Nevada law. This amendment to the merger agree", "url": "https://www.stocktitan.net/sec-filings/XOMA/8-k-xoma-royalty-corp-reports-material-event-22c6c1665a5f.html", "source_name": "Stock Titan", "published_at": "2026-05-18T13:09:33", "published_display": "18 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake", "summary": "Ligand Pharmaceuticals has announced a takeover plan for XOMA Royalty Corporation, acquiring a 47.0% stake through voting and support agreements. The deal, filed on May 1, 2026, involves Ligand purchasing XOMA for $39 per share in cash plus contingent value rights. This acquisiti", "url": "https://www.tradingview.com/news/tradingview:6c73d9d0e4628:0-ligand-pharmaceuticals-launches-takeover-plan-at-xoma-royalty-corporation-with-47-0-stake/", "source_name": "TradingView", "published_at": "2026-05-02T01:10:05", "published_display": "02 May 2026 01:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Appian Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday", "summary": "Morgan Stanley analyst Sanjit Singh downgraded Appian Corp (APPN) from Overweight to Equal-Weight, cutting its price target from $41 to $25. Additionally, HC Wainwright & Co. analyst Joseph Pantginis downgraded XOMA Royalty Corp (XOMA) from Buy to Neutral with a $39 price target.", "url": "https://www.sahmcapital.com/news/content/this-appian-analyst-is-no-longer-bullish-here-are-top-2-downgrades-for-thursday-2026-04-30", "source_name": "Sahm", "published_at": "2026-05-01T22:10:05", "published_display": "01 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm", "summary": "The Schall Law Firm is investigating potential breaches of fiduciary duty by the directors and management of XOMA Royalty Corporation following the company's announcement of its acquisition by Ligand Pharmaceuticals for $739 million. Shareholders of XOMA are encouraged to partici", "url": "https://www.globenewswire.com/news-release/2026/04/28/3283302/0/en/xoma-investors-have-the-opportunity-to-join-investigation-of-xoma-royalty-corporation-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T17:40:00", "published_display": "28 Apr 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOc05FakI2ZUxYckZ1ZzRXOTRuNkJwOUctbmRvaWo4SVB4b1REZ1R0Z2pPVVRIZ3FhVktUamlYRElPUDg4MUhHMXRBQmNXanNOaE5yY0JoT1ZYclNJZXNPV3BZQkZXd1c3WW1UOFZZT3FCeFFJMzVYeFlsSUJNd0FoVGZjX3ZvN1JCdWZzYlMzelRidW9hUGc?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to acquire XOMA Royalty", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOYnNadm1FNV9FMTl1enRVYWhlRzBlTFRhdWpfa2VBWUYxaGIxeE1wVDhlZy1MY0FLWTA1bEZOVEhoOE1FclVFTzFkaXl0WlFqLVhLWlZnM21zcDNlV3NOQ3haOVdfeVcwbkZ6NFpaNUh2Nmw3bXBqaHNPckd5b3BNWg?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to Acquire XOMA Royalty, Further Accelerating Profit", "summary": "Ligand Pharmaceuticals has announced its definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million in cash at $39.00 per share. This acquisition is expected to significantly expand Ligand's royalty portfolio to over 200 assets, including seven new co", "url": "https://www.globenewswire.com/news-release/2026/04/27/3281484/7281/en/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T05:08:58", "published_display": "28 Apr 2026 05:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ademi LLP Investigates Whether XOMA Royalty Corporation Is Obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating whether XOMA Royalty Corporation is securing a fair price for its public shareholders in its proposed transaction. The firm is examining if XOMA's board and management have upheld their fiduciary duties and if the transaction terms are equitable. Public", "url": "https://www.moomoo.com/news/post/68944830/shareholder-alert-ademi-llp-investigates-whether-xoma-royalty-corporation-is", "source_name": "Moomoo", "published_at": "2026-04-28T05:08:58", "published_display": "28 Apr 2026 05:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million", "summary": "Ligand Pharmaceuticals is acquiring XOMA Royalty for over $700 million, aiming to significantly expand its biopharma royalty portfolio and enhance long-term growth. The acquisition, valued at $39.00 per share in cash, is expected to be immediately accretive to Ligand's adjusted E", "url": "https://www.benzinga.com/m-a/26/04/52072759/ligand-bets-on-royalty-growth-with-xoma-buyout-worth-over-700-million", "source_name": "Benzinga", "published_at": "2026-04-27T17:38:51", "published_display": "27 Apr 2026 17:38", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand\u2019s Position as a Leading Biopharma Royalty Aggregator", "summary": "Ligand Pharmaceuticals (LGND) will acquire XOMA Royalty (XOMA) for $39.00 per share in cash, totaling approximately $739 million, plus a non-transferable Contingent Value Right (CVR) per share tied to potential litigation proceeds. This acquisition is expected to add seven market", "url": "https://www.stocktitan.net/news/XOMA/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-2wxerljpu7c8.html", "source_name": "Stock Titan", "published_at": "2026-04-27T16:39:44", "published_display": "27 Apr 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday", "summary": "XOMA Royalty, Oruka Therapeutics, and Repay Holdings were among several stocks that saw significant gains on Monday. XOMA Royalty surged after Ligand Pharmaceuticals announced plans to acquire it for $39.00 per share, while Oruka Therapeutics and Veradermics Inc rallied on positi", "url": "https://www.benzinga.com/news/26/04/52064652/xoma-royalty-oruka-therapeutics-repay-holdings-and-other-big-stocks-moving-higher-on-monday", "source_name": "Benzinga", "published_at": "2026-04-27T14:10:46", "published_display": "27 Apr 2026 14:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder Alert: Ademi LLP investigates whether XOMA Royalty Corporation is obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating XOMA (NASDAQ: XOMA) for potential breaches of fiduciary duty related to its recently announced transaction with Ligand. The firm is examining whether the $39.00 per share cash price, totaling approximately $739 million plus a contingent value right, rep", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-xoma-royalty-corporation-is-obtaining-a-fair-price-for-public-shareholders-302754185.html", "source_name": "PR Newswire", "published_at": "2026-04-27T14:10:46", "published_display": "27 Apr 2026 14:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million", "summary": "Ligand Pharmaceuticals announced its acquisition of XOMA Royalty for approximately $739 million in cash. This deal will add over 120 treatments to Ligand's portfolio, including seven marketed products, boosting its total to more than 200 drugs. Ligand expects the acquisition to b", "url": "https://www.reuters.com/legal/transactional/ligand-pharma-buy-fellow-biotech-royalty-rights-buyer-xoma-739-million-2026-04-27/", "source_name": "Reuters", "published_at": "2026-04-27T12:12:00", "published_display": "27 Apr 2026 12:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to buy XOMA Royalty (Nasdaq: XOMA) in $739M cash and CVR deal", "summary": "Ligand Pharmaceuticals has agreed to acquire XOMA Royalty Corporation for approximately $739 million, with XOMA stockholders receiving $39.00 per share in cash plus contingent value rights (CVRs) tied to potential proceeds from Janssen-related litigation. This deal offers XOMA sh", "url": "https://www.stocktitan.net/sec-filings/XOMA/8-k-xoma-royalty-corp-reports-material-event-117346a06323.html", "source_name": "Stock Titan", "published_at": "2026-04-27T12:10:46", "published_display": "27 Apr 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating the sale of XOMA Royalty Corporation (NASDAQ: XOMA) to Ligand Pharmaceuticals Incorporated for $39.00 per share. The firm is examining whether XOMA and its board of directors failed to obtain the best possible price ", "url": "https://www.businesswire.com/news/home/20260427148351/en/XOMA-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-XOMA-Royalty-Corporation-is-Obtaining-a-Fair-Price-for-its-Shareholders", "source_name": "Business Wire", "published_at": "2026-04-27T12:10:46", "published_display": "27 Apr 2026 12:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQMzZDZWF5N1VUcTI5MkJmakpuWW5TdEUxYnFxNlQ0QWdGZ3BTRFBXQ2xDYVNIdGN3MngyRWloc1ZBMFlJMXNkTWpvYUFRanBCMDllOFVYeS1ZNG9OcXNDamlzdlI5OVNKbURsdUNIaWlmcVBQanpuam00ZlEza19OcnVweE0?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "XOMA Royalty (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?", "summary": "XOMA Royalty (NASDAQ:XOMA) stock recently traded above its 200-day moving average, reaching $40.15 before settling at $39.37. The company beat quarterly earnings and revenue expectations with a significant net margin, leading to a \"Moderate Buy\" consensus from analysts, who proje", "url": "https://www.marketbeat.com/instant-alerts/xoma-royalty-nasdaqxoma-share-price-passes-above-two-hundred-day-moving-average-should-you-sell-2026-04-23/", "source_name": "MarketBeat", "published_at": "2026-04-24T03:09:56", "published_display": "24 Apr 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright & Co. maintains XOMA Royalty (XOMA) buy recommendation", "summary": "This article states that HC Wainwright & Co. has reiterated its buy recommendation for XOMA Royalty (XOMA). No additional details are provided in the current content.", "url": "http://www.msn.com/en-us/money/companies/hc-wainwright-co-maintains-xoma-royalty-xoma-buy-recommendation/ar-AA1Scxlf?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-t", "source_name": "MSN", "published_at": "2026-04-23T15:38:52", "published_display": "23 Apr 2026 15:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) CEO Owen Hughes exercises 10,568 PSUs and updates holdings", "summary": "XOMA Royalty Corp CEO Owen Hughes exercised 10,568 Performance Stock Units (PSUs) on April 20, 2026, receiving an equal number of common stock shares. Following this transaction, his direct holdings increased to 191,264 common shares, with an additional 295 indirectly held throug", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-9468a9fcc9fa.html", "source_name": "Stock Titan", "published_at": "2026-04-22T20:10:26", "published_display": "22 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) CFO converts 11,538 Performance Stock Units into common shares", "summary": "XOMA Royalty Corp's CFO, Jeffrey Trigilio, converted 11,538 Performance Stock Units (PSUs) into an equal number of common shares on April 20, 2026, at an exercise price of $0.00 per share. Following this transaction, Mr. Trigilio directly holds 103,906 shares of common stock and ", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-42c3778f4750.html", "source_name": "Stock Titan", "published_at": "2026-04-22T20:10:26", "published_display": "22 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) legal chief converts 3,370 PSUs into common shares", "summary": "XOMA Royalty Corp's Chief Legal Officer, Maricel Perea Montano, converted 3,370 Performance Stock Units (PSUs) into common shares on April 20, 2026, at $0.00 per share. This transaction increased her direct holdings to 41,793 common shares, with 37,074 PSUs remaining outstanding ", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-0542ccc83fcb.html", "source_name": "Stock Titan", "published_at": "2026-04-22T20:10:26", "published_display": "22 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Xoma Royalty Corp (XOMA). It indicates a 'Strong Buy' overall technical sentiment based on a combination of moving averages and oscillators, despite some indicators suggesting a 'Sell' condition due to the st", "url": "https://intellectia.ai/en/stock/XOMA/technical", "source_name": "Intellectia AI", "published_at": "2026-04-22T17:10:26", "published_display": "22 Apr 2026 17:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How (XOMAP) Movements Inform Risk Allocation Models", "summary": "This article analyzes Xoma Corporation's (NASDAQ: XOMAP) stock movements and provides three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles. It highlights conflicting sentiment across various time horizons, sugg", "url": "https://news.stocktradersdaily.com/news_release/78/How_XOMAP_Movements_Inform_Risk_Allocation_Models_041626063002_1776378602.html", "source_name": "Stock Traders Daily", "published_at": "2026-04-16T18:08:38", "published_display": "16 Apr 2026 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) CFO exercises 4,000 PSUs, 1,632 shares withheld for taxes", "summary": "XOMA Royalty Corp's CFO, Jeffrey Trigilio, exercised 4,000 Performance Stock Units (PSUs), converting them into 4,000 common shares. To cover tax obligations, 1,632 shares were withheld through a non-open market transaction at $36.76 per share. Following these transactions, Trigi", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-ffca8afdf8b0.html", "source_name": "Stock Titan", "published_at": "2026-04-16T00:39:52", "published_display": "16 Apr 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of \"Moderate Buy\" from Brokerages", "summary": "XOMA Royalty Corporation (NASDAQ:XOMA) has received an average \"Moderate Buy\" rating from six brokerages, with an average 12-month price target of $61.60. Despite beating earnings estimates in its last quarter, analysts forecast a negative EPS for the current fiscal year. Institu", "url": "https://www.marketbeat.com/instant-alerts/xoma-royalty-corporation-nasdaqxoma-receives-average-rating-of-moderate-buy-from-brokerages-2026-04-15/", "source_name": "MarketBeat", "published_at": "2026-04-15T11:39:52", "published_display": "15 Apr 2026 11:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turnstone Biologics to be acquired by XOMA Royalty", "summary": "The article states that Turnstone Biologics is set to be acquired by XOMA Royalty. No further details about the acquisition or the companies involved are provided.", "url": "http://www.msn.com/en-us/health/other/turnstone-biologics-to-be-acquired-by-xoma-royalty/ar-AA1HxeKD?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-04-14T09:09:18", "published_display": "14 Apr 2026 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (XOMAO)", "summary": "This article provides an AI-driven analysis of Xoma Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (NASDAQ: XOMAO), highlighting a neutral near-term sentiment with a mid-channel oscillation pattern. It outlines three distinct trading strategies\u2014posit", "url": "https://news.stocktradersdaily.com/news_release/101/Understanding_Momentum_Shifts_in_XOMAO_041326015401_1776102841.html", "source_name": "Stock Traders Daily", "published_at": "2026-04-13T13:54:00", "published_display": "13 Apr 2026 13:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA SEC Filings - XOMA Royalty Corporation 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to SEC filings for XOMA Royalty Corporation (XOMA), including 10-K, 10-Q, 8-K, and Form 4 documents, enhanced with AI-powered summaries. Recent filings detail Q3 2025 financial results, an updated tender offer for LAVA Therapeutics, \"at the market\" sales", "url": "https://www.stocktitan.net/sec-filings/XOMA/page-4.html", "source_name": "Stock Titan", "published_at": "2026-04-05T13:08:52", "published_display": "05 Apr 2026 13:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNaGt0ZWVvdnRkNDQ0QmxnaVBYaGhER0ZOdDg3TXJRN3pCcEJZZndQUDd4bnRLOVJRVGcwLVlKYjYzX1V0ZUc5ekZWVmh3Wm95aUVEbHZTUTFoVG5pd0xFREcxR3pSWS1rY1ZPTmlsQzlJYVo4akdXOE5SbnFJTS1FbkZLdVBoeHVSYzhpczdJRkViSkU2NDk1aVVRSlVuejA?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (XOMA) Trailing Profitability Turnaround Challenges Skeptical Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNakNMaG1LSFpZNWVlMm02S0dNaEplcVpZdjYwNkNLV3F0VWNsVk1TVkg5d2JBUGZSYUJ1Y2VqME1aR0ZKdUcyS1dHemd5alo1MkVzVHItRER6WVhnWm1UaDgyVE1IU1RuNHk2T0hsMDd2aTBWWVQ5VlFBTVh3bXFMaG5UdGZtZ1I0cnJSNF96LXFuVl9IOFJXT3M2THhEQVlveXc2NEhpLUNzSzJJMTRMWjA5VmhUTmM1QjlOeDBucWRHMWxhajdON2FjYkIzZHAxMENUdF82ZjNCUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 13D/A XOMA Royalty Corp For: 16 July By Investing.com", "summary": "This article reports on a Form 13D/A filing by XOMA Royalty Corp for July 16, 2026. The filing is a standard disclosure document related to equity ownership. The content primarily consists of navigational elements and market data, with the filing announcement being the central pi", "url": "https://ng.investing.com/news/stock-market-news/form-13da-xoma-royalty-corp-for-16-july-93CH-2604017", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T02:39:10", "published_display": "17 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) holders tender shares in Ligand merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPaXNxb3V4MDZMY21VWUN2VGRrZFo2eGJLOURfVmJCMGdaZ2x6UGtZWXRRZ0czOW1hUEltaDU4NFBPaUlRUTNMSWRXVUhsa0RWTlZTQWpkTDBONXRLTjNpX3RFa0FYTElkZFhQTk5qRUxFYTZ4TldZZ2RlcnZONTc3UUR2X0hfMHJvd0licDBTRkhSQUo0ckppaVNLdFBGRllRU01pcGQ3WW9ZWDVBMnRHcQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T21:03:19+00:00", "published_display": "16 Jul 2026 21:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) investors cashed out at $39 per share in Ligand merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPQ1diQmdFalRMN1JqVlo4NDlldl9PbjdBbS1iVF9oQ0NVaDh5QWU5U1IyaHkyWndmclR3b25Wb2JYTzVTTHdpaFl3T2JYWU1LNVVvRGdWeDY4SEpzb0p5WWVXMmFWSnNiNmRhUGF0SU0zZ0Joel84T2hKLXF4ZEZqUmZGNl9SWTBiS1BTcmhBWm5GYmtHX09NRHlfbW1DdFNzVDhFcXBoaHVBekF3cnlBelMyUmhOcHdaSTBqdUJrb3h6NVFjeVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T21:01:11+00:00", "published_display": "16 Jul 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (NASDAQ: XOMA) files Form 25 to delist preferred shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPb2lvZlVrZHlGRWVBelFiWEJHdzlPakg5cGhKRWZrTGwxWkQ0SzlDSVU2NVBZZl9mdzhGY2FfYlZSYjdTRkxJTjBRU3puMG9pVnUtWVFzSk5SOU5zREdzcFRVXzBDM2xlbkZqMDI1N0trd3o1eXR1N3k0aTBsS2xrV3lMVEwtTHFHdGZXaHFGTURHN3Y0SU8zSVFUc3Nfdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:31:41+00:00", "published_display": "16 Jul 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (Nasdaq: XOMA) common stock removed from Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcDdKSElNSGpjbzdxWWE2Y1FGY29obXprM2FOSDJwQTQxamhTdUxLUW95T1Vja2V1SlBJMGhCRG8tZXR6bVhZLS1NM2l6MnZNSEdaWGhZRXJEY0tTN0xGNUx0X1dqNFdvVFY3SlNrX05Oc014TExQLXVlRjFFQlVRUExHRWRuWE9lS0hKU1V6Sk84UkVJS0JnRzc2M1d6UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T14:39:49+00:00", "published_display": "15 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (NASDAQ: XOMA) director\u2019s stock canceled in $39 cash-and-CVR deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNZUN5T3BaNDJNQXpQdVdsNVlwZ3BtWEFNLU9YTmNIcGl0RS1VOUg4am8zSjBwQzlBZFBIYlVjaTN5dE5TRk1LZVVkdmszeUsySTdINWVnN2JocDktYW1vUFlNTXFDNUgtak1Yd290N2thc0p6MHhIQjRWTTRoRm9iU2JadlJIeUg4X0VXMHVxeVdYQ1RSWHRxaWx5NklKSUc1aHNwU1lpcmVlM1JFdmVscw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T02:15:09+00:00", "published_display": "15 Jul 2026 02:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) legal chief\u2019s stock and PSUs converted in Ligand merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOWFE0YnZROHY5by1oS2U3UkUzaHZmZ19hSFRnUGpPSGwzeXdjWW9Fc2p2eW5fUzFjdVVSbVR3NkN3WDNmOVFSTS1maXllTTduNGZYMjBHZTJ2eTl4MWI1NjlBSWRfUzFXci01WFNJVGhXN29jbEV4Z1B2c2NEcV9aWjlObkxfTXBzM3piZVVxTGstUVFsLXdWTWFHOFltY2JxeVZBQWtIay13djE0NDE2SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T02:15:09+00:00", "published_display": "15 Jul 2026 02:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) CEO cashes out at $39 per share in Ligand merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQVGtFSmY2Nm14Wld5MVdlMnJnZEdHWENfaE44TmlrM19kWnlJSzZkQm9rNDhlbjlTeHd6andGWEFWX2RZNzVSaGo0SkJCRXg4X25KODZHOVFpTHluQjJUbEdPdzFnX2V5LXlTUUtCWEZvdVpUZUpIaGV5QkpQb25BSlJyQTZDWG9QMGVCaTlmcnRsOEtWbnRHSUx3M3pDMDhSamx2UzY5RWlfMDF1dFRsMw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T02:15:09+00:00", "published_display": "15 Jul 2026 02:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corp (XOMA) director exits stake as shares convert to $39 cash and CVRs", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNcDY5VC1uZHhWY3BuZDJNbVRuMnRTZkdRZDFEcEVGZW53dk9yOWdPUUpWRklqWG5mbV9KVnFteWxyNmVBVU5wT1NQX0pvc21qTS00aUxYckZ4SzNaTHlCc1ZtdXlNVnVTR241ZERXaWFaZGxYWENKaG5hbVZmcm94UENCblhqZV9LRWZfY3Zmc1NsWXpLcjgyQ1RKX3J0c2FyaGJmNGo3QUNEUDRYOF9MNg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T02:15:09+00:00", "published_display": "15 Jul 2026 02:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand merger cashes out XOMA Royalty Corp (XOMA) director\u2019s shares and options", "summary": "XOMA Royalty Corp director Jack L. Wyszomierski reported the disposition of 21,828 common shares and the cancellation of all stock options due to XOMA's merger with Ligand Pharmaceuticals. Each share was converted into the right to receive $39.00 in cash plus contingent value rig", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-6f67b0ba9a58.html", "source_name": "Stock Titan", "published_at": "2026-07-15T02:44:20", "published_display": "15 Jul 2026 02:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ligand-pharmaceuticals-closes-739-million-140015736.html", "source_name": "MT Newswires", "published_at": "2026-07-14T14:00:15+00:00", "published_display": "14 Jul 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Announces Closing of Its Acquisition by Ligand", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxORE84QkVUVG5LRnpVOGZxdkNhMnpIb0JJc1hwRkpNLXQ0SnlzbWFnUUhVWjV1Vlk2c3U1VTJ3T3Q3UTRPbW1iZU1rZ1g2WllVLW9kOV9uSjN3VmdhN196R2JwZFphRGsybFR2S2RGTGFaWDlhWEhpU0E1aEpCSnhUaWlSTDEtaFNNdkp5ZzdmcTNacG9WRlVvd2tnYXJORjdCcjM4dVd3?oc=5", "source_name": "Market source", "published_at": "2026-07-14T13:00:00+00:00", "published_display": "14 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ligand-completes-acquisition-xoma-royalty-130000838.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T13:00:00+00:00", "published_display": "14 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand\u2019s Portfolio Now Tops 200 Biopharmaceutical Royalty Assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcTBHWFJ3d25VTVZ3M2JScUhyTkIxZnZvTE02eDFOcXV3MTh2VS1DaVdRT1oyUlRpMnZCdFVhWm9TYm1yV1p5TXBMMHVoZ1pmUFoyYmhLbDB3SUJYYXVJeng2dE5zRlVWYmYydTRFSmFsVUNYZ2Rsbzd5eDJRSXFBdVNKTWdCQ1VQbS1TODA3UXJVcklXd0ppTFZKTThZQzRGcDNuQjhxWml4MUE1MEhRMFhTUnNiR19WbkxyVHM4V0c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Leaves Nasdaq as Ligand Acquisition Closes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMFhRT3FvZEdkbFRlYXB0SWhKczR4eVBUdmxqZEJHN0tmWWl6OVp2RENXNEo2WGN4LXg0dzhSNzNGRTE0c0FNWDgwellaTnVXZnU1eEF6anQ3RHhVcFpMWXdhRGh6bk55QjlRZDhPWDdmNnFKNmtMeUNiOHZrYXNydUw5Q0ZrSG5qcDAyVlRpd3Q1TWZGZFpjZGljYkhIbC1yS0ptZ2sxT3J0cWs?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNYUtTTU51VF92YnF6MUVla010MzV4OGJfLWJWUXZoUURHOE5HOW9aWWNaVy1KWUVId1JyMElrTXBUTEl1LTdRel9jYkhsZlFsTGZYNDRSTDJxYktFVnRqTll0MGpDWVVuLXRGTnh3Zjk2eE5yWGJHTUlJQi1walNSYW9ia0hBdGJFamNLaThFXzFXa2FqaUJKYw?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) to redeem all preferred shares and issue CVRs ahead of Ligand deal", "summary": "XOMA Royalty Corporation announced plans to redeem all outstanding Series A and Series B preferred shares on July 14, 2026, at $25.00 per share plus accrued dividends, ahead of its acquisition by Ligand Pharmaceuticals. The company also declared quarterly dividends for these pref", "url": "https://www.stocktitan.net/sec-filings/XOMAP/8-k-xoma-royalty-corp-reports-material-event-91a4127e2a53.html", "source_name": "Stock Titan", "published_at": "2026-06-13T00:40:31", "published_display": "13 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corporation Declares Quarterly Preferred Stock", "summary": "XOMA Royalty Corporation announced cash dividends for its Series A and Series B Preferred Stockholders, with dividend payments scheduled for July 15, 2026. The company also declared its intention to redeem all outstanding shares of Preferred Stock on July 14, 2026, coinciding wit", "url": "https://www.globenewswire.com/news-release/2026/06/12/3311310/0/en/XOMA-Royalty-Corporation-Declares-Quarterly-Preferred-Stock-Dividend-and-Announces-Redemption-of-Its-Perpetual-Preferred-Stock-and-CVR-Dividend-Record-Date.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T20:10:05", "published_display": "12 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNU2JjaC0tQUh0d2M5dFI3NExCTW9YMW41OTFYMzFXdndiUEQ1aFpDVGhJUGRwdzJjajhISks4VEVETnBFLXdrcG90ck1PYzMxSDhlc0gzZDhWUkhJekVaLS03VldYUUpaZHA3WVBuZ3dJYVh4RFcxZGpiS0t4SlU3alNKSVZjWTN1ZFZpUTdHQUF6VXFPZXhMOFFtME1xQXdRM0QySzRHTGl3bXNh?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Saying Goodbye To The XOMA Royalty PFDs (NASDAQ:XOMAO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNZTlxak5hLWtjRXZXS3h6NG5yMkJmS0xNa0pEdXZRWTZfTUxWbVR1Q002dFphSnMxdk9aWG1GNVB2b2ZDSU1NY2x3TTBqampMZUdyT0R2UFJpVFNXcW5NZDh5SElqSHBaZ2xKN2x2WDVZV2VPTGpCTVZVLWlCOWp0N0h5ZTZzb1U?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (XOMA) adds new holding company to structure of Ligand acquisition", "summary": "XOMA Royalty Corporation has updated the structure of its acquisition by Ligand Pharmaceuticals by adding a new wholly-owned subsidiary, XOMA Royalty Holdings Corporation (HoldCo), to facilitate a holding company reorganization under Nevada law. This amendment to the merger agree", "url": "https://www.stocktitan.net/sec-filings/XOMA/8-k-xoma-royalty-corp-reports-material-event-22c6c1665a5f.html", "source_name": "Stock Titan", "published_at": "2026-05-18T13:09:33", "published_display": "18 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake", "summary": "Ligand Pharmaceuticals has announced a takeover plan for XOMA Royalty Corporation, acquiring a 47.0% stake through voting and support agreements. The deal, filed on May 1, 2026, involves Ligand purchasing XOMA for $39 per share in cash plus contingent value rights. This acquisiti", "url": "https://www.tradingview.com/news/tradingview:6c73d9d0e4628:0-ligand-pharmaceuticals-launches-takeover-plan-at-xoma-royalty-corporation-with-47-0-stake/", "source_name": "TradingView", "published_at": "2026-05-02T01:10:05", "published_display": "02 May 2026 01:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Appian Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday", "summary": "Morgan Stanley analyst Sanjit Singh downgraded Appian Corp (APPN) from Overweight to Equal-Weight, cutting its price target from $41 to $25. Additionally, HC Wainwright & Co. analyst Joseph Pantginis downgraded XOMA Royalty Corp (XOMA) from Buy to Neutral with a $39 price target.", "url": "https://www.sahmcapital.com/news/content/this-appian-analyst-is-no-longer-bullish-here-are-top-2-downgrades-for-thursday-2026-04-30", "source_name": "Sahm", "published_at": "2026-05-01T22:10:05", "published_display": "01 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm", "summary": "The Schall Law Firm is investigating potential breaches of fiduciary duty by the directors and management of XOMA Royalty Corporation following the company's announcement of its acquisition by Ligand Pharmaceuticals for $739 million. Shareholders of XOMA are encouraged to partici", "url": "https://www.globenewswire.com/news-release/2026/04/28/3283302/0/en/xoma-investors-have-the-opportunity-to-join-investigation-of-xoma-royalty-corporation-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T17:40:00", "published_display": "28 Apr 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOc05FakI2ZUxYckZ1ZzRXOTRuNkJwOUctbmRvaWo4SVB4b1REZ1R0Z2pPVVRIZ3FhVktUamlYRElPUDg4MUhHMXRBQmNXanNOaE5yY0JoT1ZYclNJZXNPV3BZQkZXd1c3WW1UOFZZT3FCeFFJMzVYeFlsSUJNd0FoVGZjX3ZvN1JCdWZzYlMzelRidW9hUGc?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to acquire XOMA Royalty", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOYnNadm1FNV9FMTl1enRVYWhlRzBlTFRhdWpfa2VBWUYxaGIxeE1wVDhlZy1MY0FLWTA1bEZOVEhoOE1FclVFTzFkaXl0WlFqLVhLWlZnM21zcDNlV3NOQ3haOVdfeVcwbkZ6NFpaNUh2Nmw3bXBqaHNPckd5b3BNWg?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to Acquire XOMA Royalty, Further Accelerating Profit", "summary": "Ligand Pharmaceuticals has announced its definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million in cash at $39.00 per share. This acquisition is expected to significantly expand Ligand's royalty portfolio to over 200 assets, including seven new co", "url": "https://www.globenewswire.com/news-release/2026/04/27/3281484/7281/en/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T05:08:58", "published_display": "28 Apr 2026 05:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ademi LLP Investigates Whether XOMA Royalty Corporation Is Obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating whether XOMA Royalty Corporation is securing a fair price for its public shareholders in its proposed transaction. The firm is examining if XOMA's board and management have upheld their fiduciary duties and if the transaction terms are equitable. Public", "url": "https://www.moomoo.com/news/post/68944830/shareholder-alert-ademi-llp-investigates-whether-xoma-royalty-corporation-is", "source_name": "Moomoo", "published_at": "2026-04-28T05:08:58", "published_display": "28 Apr 2026 05:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million", "summary": "Ligand Pharmaceuticals is acquiring XOMA Royalty for over $700 million, aiming to significantly expand its biopharma royalty portfolio and enhance long-term growth. The acquisition, valued at $39.00 per share in cash, is expected to be immediately accretive to Ligand's adjusted E", "url": "https://www.benzinga.com/m-a/26/04/52072759/ligand-bets-on-royalty-growth-with-xoma-buyout-worth-over-700-million", "source_name": "Benzinga", "published_at": "2026-04-27T17:38:51", "published_display": "27 Apr 2026 17:38", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand\u2019s Position as a Leading Biopharma Royalty Aggregator", "summary": "Ligand Pharmaceuticals (LGND) will acquire XOMA Royalty (XOMA) for $39.00 per share in cash, totaling approximately $739 million, plus a non-transferable Contingent Value Right (CVR) per share tied to potential litigation proceeds. This acquisition is expected to add seven market", "url": "https://www.stocktitan.net/news/XOMA/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-2wxerljpu7c8.html", "source_name": "Stock Titan", "published_at": "2026-04-27T16:39:44", "published_display": "27 Apr 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday", "summary": "XOMA Royalty, Oruka Therapeutics, and Repay Holdings were among several stocks that saw significant gains on Monday. XOMA Royalty surged after Ligand Pharmaceuticals announced plans to acquire it for $39.00 per share, while Oruka Therapeutics and Veradermics Inc rallied on positi", "url": "https://www.benzinga.com/news/26/04/52064652/xoma-royalty-oruka-therapeutics-repay-holdings-and-other-big-stocks-moving-higher-on-monday", "source_name": "Benzinga", "published_at": "2026-04-27T14:10:46", "published_display": "27 Apr 2026 14:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder Alert: Ademi LLP investigates whether XOMA Royalty Corporation is obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating XOMA (NASDAQ: XOMA) for potential breaches of fiduciary duty related to its recently announced transaction with Ligand. The firm is examining whether the $39.00 per share cash price, totaling approximately $739 million plus a contingent value right, rep", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-xoma-royalty-corporation-is-obtaining-a-fair-price-for-public-shareholders-302754185.html", "source_name": "PR Newswire", "published_at": "2026-04-27T14:10:46", "published_display": "27 Apr 2026 14:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million", "summary": "Ligand Pharmaceuticals announced its acquisition of XOMA Royalty for approximately $739 million in cash. This deal will add over 120 treatments to Ligand's portfolio, including seven marketed products, boosting its total to more than 200 drugs. Ligand expects the acquisition to b", "url": "https://www.reuters.com/legal/transactional/ligand-pharma-buy-fellow-biotech-royalty-rights-buyer-xoma-739-million-2026-04-27/", "source_name": "Reuters", "published_at": "2026-04-27T12:12:00", "published_display": "27 Apr 2026 12:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to buy XOMA Royalty (Nasdaq: XOMA) in $739M cash and CVR deal", "summary": "Ligand Pharmaceuticals has agreed to acquire XOMA Royalty Corporation for approximately $739 million, with XOMA stockholders receiving $39.00 per share in cash plus contingent value rights (CVRs) tied to potential proceeds from Janssen-related litigation. This deal offers XOMA sh", "url": "https://www.stocktitan.net/sec-filings/XOMA/8-k-xoma-royalty-corp-reports-material-event-117346a06323.html", "source_name": "Stock Titan", "published_at": "2026-04-27T12:10:46", "published_display": "27 Apr 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating the sale of XOMA Royalty Corporation (NASDAQ: XOMA) to Ligand Pharmaceuticals Incorporated for $39.00 per share. The firm is examining whether XOMA and its board of directors failed to obtain the best possible price ", "url": "https://www.businesswire.com/news/home/20260427148351/en/XOMA-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-XOMA-Royalty-Corporation-is-Obtaining-a-Fair-Price-for-its-Shareholders", "source_name": "Business Wire", "published_at": "2026-04-27T12:10:46", "published_display": "27 Apr 2026 12:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQMzZDZWF5N1VUcTI5MkJmakpuWW5TdEUxYnFxNlQ0QWdGZ3BTRFBXQ2xDYVNIdGN3MngyRWloc1ZBMFlJMXNkTWpvYUFRanBCMDllOFVYeS1ZNG9OcXNDamlzdlI5OVNKbURsdUNIaWlmcVBQanpuam00ZlEza19OcnVweE0?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?", "summary": "XOMA Royalty (NASDAQ:XOMA) stock recently traded above its 200-day moving average, reaching $40.15 before settling at $39.37. The company beat quarterly earnings and revenue expectations with a significant net margin, leading to a \"Moderate Buy\" consensus from analysts, who proje", "url": "https://www.marketbeat.com/instant-alerts/xoma-royalty-nasdaqxoma-share-price-passes-above-two-hundred-day-moving-average-should-you-sell-2026-04-23/", "source_name": "MarketBeat", "published_at": "2026-04-24T03:09:56", "published_display": "24 Apr 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright & Co. maintains XOMA Royalty (XOMA) buy recommendation", "summary": "This article states that HC Wainwright & Co. has reiterated its buy recommendation for XOMA Royalty (XOMA). No additional details are provided in the current content.", "url": "http://www.msn.com/en-us/money/companies/hc-wainwright-co-maintains-xoma-royalty-xoma-buy-recommendation/ar-AA1Scxlf?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-t", "source_name": "MSN", "published_at": "2026-04-23T15:38:52", "published_display": "23 Apr 2026 15:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) CEO Owen Hughes exercises 10,568 PSUs and updates holdings", "summary": "XOMA Royalty Corp CEO Owen Hughes exercised 10,568 Performance Stock Units (PSUs) on April 20, 2026, receiving an equal number of common stock shares. Following this transaction, his direct holdings increased to 191,264 common shares, with an additional 295 indirectly held throug", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-9468a9fcc9fa.html", "source_name": "Stock Titan", "published_at": "2026-04-22T20:10:26", "published_display": "22 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) CFO converts 11,538 Performance Stock Units into common shares", "summary": "XOMA Royalty Corp's CFO, Jeffrey Trigilio, converted 11,538 Performance Stock Units (PSUs) into an equal number of common shares on April 20, 2026, at an exercise price of $0.00 per share. Following this transaction, Mr. Trigilio directly holds 103,906 shares of common stock and ", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-42c3778f4750.html", "source_name": "Stock Titan", "published_at": "2026-04-22T20:10:26", "published_display": "22 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) legal chief converts 3,370 PSUs into common shares", "summary": "XOMA Royalty Corp's Chief Legal Officer, Maricel Perea Montano, converted 3,370 Performance Stock Units (PSUs) into common shares on April 20, 2026, at $0.00 per share. This transaction increased her direct holdings to 41,793 common shares, with 37,074 PSUs remaining outstanding ", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-0542ccc83fcb.html", "source_name": "Stock Titan", "published_at": "2026-04-22T20:10:26", "published_display": "22 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Xoma Royalty Corp (XOMA). It indicates a 'Strong Buy' overall technical sentiment based on a combination of moving averages and oscillators, despite some indicators suggesting a 'Sell' condition due to the st", "url": "https://intellectia.ai/en/stock/XOMA/technical", "source_name": "Intellectia AI", "published_at": "2026-04-22T17:10:26", "published_display": "22 Apr 2026 17:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (XOMAP) Movements Inform Risk Allocation Models", "summary": "This article analyzes Xoma Corporation's (NASDAQ: XOMAP) stock movements and provides three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles. It highlights conflicting sentiment across various time horizons, sugg", "url": "https://news.stocktradersdaily.com/news_release/78/How_XOMAP_Movements_Inform_Risk_Allocation_Models_041626063002_1776378602.html", "source_name": "Stock Traders Daily", "published_at": "2026-04-16T18:08:38", "published_display": "16 Apr 2026 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA (XOMA) CFO exercises 4,000 PSUs, 1,632 shares withheld for taxes", "summary": "XOMA Royalty Corp's CFO, Jeffrey Trigilio, exercised 4,000 Performance Stock Units (PSUs), converting them into 4,000 common shares. To cover tax obligations, 1,632 shares were withheld through a non-open market transaction at $36.76 per share. Following these transactions, Trigi", "url": "https://www.stocktitan.net/sec-filings/XOMA/form-4-xoma-royalty-corp-insider-trading-activity-ffca8afdf8b0.html", "source_name": "Stock Titan", "published_at": "2026-04-16T00:39:52", "published_display": "16 Apr 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of \"Moderate Buy\" from Brokerages", "summary": "XOMA Royalty Corporation (NASDAQ:XOMA) has received an average \"Moderate Buy\" rating from six brokerages, with an average 12-month price target of $61.60. Despite beating earnings estimates in its last quarter, analysts forecast a negative EPS for the current fiscal year. Institu", "url": "https://www.marketbeat.com/instant-alerts/xoma-royalty-corporation-nasdaqxoma-receives-average-rating-of-moderate-buy-from-brokerages-2026-04-15/", "source_name": "MarketBeat", "published_at": "2026-04-15T11:39:52", "published_display": "15 Apr 2026 11:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turnstone Biologics to be acquired by XOMA Royalty", "summary": "The article states that Turnstone Biologics is set to be acquired by XOMA Royalty. No further details about the acquisition or the companies involved are provided.", "url": "http://www.msn.com/en-us/health/other/turnstone-biologics-to-be-acquired-by-xoma-royalty/ar-AA1HxeKD?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-04-14T09:09:18", "published_display": "14 Apr 2026 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (XOMAO)", "summary": "This article provides an AI-driven analysis of Xoma Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (NASDAQ: XOMAO), highlighting a neutral near-term sentiment with a mid-channel oscillation pattern. It outlines three distinct trading strategies\u2014posit", "url": "https://news.stocktradersdaily.com/news_release/101/Understanding_Momentum_Shifts_in_XOMAO_041326015401_1776102841.html", "source_name": "Stock Traders Daily", "published_at": "2026-04-13T13:54:00", "published_display": "13 Apr 2026 13:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA SEC Filings - XOMA Royalty Corporation 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to SEC filings for XOMA Royalty Corporation (XOMA), including 10-K, 10-Q, 8-K, and Form 4 documents, enhanced with AI-powered summaries. Recent filings detail Q3 2025 financial results, an updated tender offer for LAVA Therapeutics, \"at the market\" sales", "url": "https://www.stocktitan.net/sec-filings/XOMA/page-4.html", "source_name": "Stock Titan", "published_at": "2026-04-05T13:08:52", "published_display": "05 Apr 2026 13:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNaGt0ZWVvdnRkNDQ0QmxnaVBYaGhER0ZOdDg3TXJRN3pCcEJZZndQUDd4bnRLOVJRVGcwLVlKYjYzX1V0ZUc5ekZWVmh3Wm95aUVEbHZTUTFoVG5pd0xFREcxR3pSWS1rY1ZPTmlsQzlJYVo4akdXOE5SbnFJTS1FbkZLdVBoeHVSYzhpczdJRkViSkU2NDk1aVVRSlVuejA?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty (XOMA) Trailing Profitability Turnaround Challenges Skeptical Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNakNMaG1LSFpZNWVlMm02S0dNaEplcVpZdjYwNkNLV3F0VWNsVk1TVkg5d2JBUGZSYUJ1Y2VqME1aR0ZKdUcyS1dHemd5alo1MkVzVHItRER6WVhnWm1UaDgyVE1IU1RuNHk2T0hsMDd2aTBWWVQ5VlFBTVh3bXFMaG5UdGZtZ1I0cnJSNF96LXFuVl9IOFJXT3M2THhEQVlveXc2NEhpLUNzSzJJMTRMWjA5VmhUTmM1QjlOeDBucWRHMWxhajdON2FjYkIzZHAxMENUdF82ZjNCUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 60, "sentiment_summary": {"positive": 18, "negative": 5, "neutral": 37, "score": 56, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 74, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 13.0, "count": 23}, {"event": "general", "label": "Market update", "weight": 10.25, "count": 18}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 40.17, "latest_week": "2026-07-17", "one_week_move": -9.2, "four_week_move": -4.1, "twelve_week_move": 6.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.493382, "market_dynamics_buy_signal": false, "relative_strength": 8.951422, "fair_value_gap": 50.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.7165, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.2% over one week, -4.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 20}, {"label": "Market source", "count": 11}, {"label": "GlobeNewswire", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "TradingView", "count": 2}, {"label": "Benzinga", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "MSN", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 23}, {"label": "Market update", "count": 18}, {"label": "Earnings", "count": 14}, {"label": "Capital return", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-9.2% over one week, -4.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 13D/A XOMA Royalty Corp For: 16 July By Investing.com"}], "updated_at": "2026-07-22T12:45:59.196182+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}